Skip to content
PatentBrief
Get alertsTop ↑

Gene Editing T-Cells to Fight CD7 Blood Cancers

This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.

Granted 2026ActiveExpires 2045Owned by Washington University in St. LouisInvented by Matthew Cooper, John F. DiPersio

Original patent title: “Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors”

Plain-English explanation by SahiLast reviewed · November 1, 2026

This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient. Granted to Washington University in St. Louis in 2026 with 31 claims, and it is expected to expire in 2045.

Coverage

What does this patent actually cover?

This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).

The gap

What does this patent NOT cover?

  • Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
  • Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
  • Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
  • Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
  • Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
  • Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 12564648
StatusActive
FieldBiotech & Medicine
AssigneeWashington University in St. Louis
InventorsMatthew Cooper, John F. DiPersio
Filed2025
Granted2026
Expires2045
Claims31
Times cited0
LitigationNone on record
Value · $108K–$346KModest

What made this novel

The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.

The Patent Drawing

Representative patent drawing for Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors (US 12564648)
Representative figure · US 12564648All figures on Google Patents →
Gene editing of CAR-T cells fo…(Primary claim)biotechpharmaceuticalgene editingoncology

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

CAR-T cell therapies for blood cancers

02

Gene-edited cell therapies

03

Treatments for T-cell acute lymphoblastic leukemia (T-ALL)

04

Treatments for T-cell lymphoblastic lymphoma (T-LBL)

05

Treatments for T-cell non-Hodgkin's Lymphoma (T-NHL)

Why it matters

The bigger picture

Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood cancers, specifically those that express CD7.

Filed

April 24, 2025

Granted

March 3, 2026

Market context

Who's building on this

Companies in this space

Washington University in St. Louis, as the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is likely to be developing this specific technology further. In the broader field of CAR-T cell therapy and gene editing for cancer, major pharmaceutical companies like Novartis, Gilead Sciences, and Bristol Myers Squibb are active. Gene editing companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are also working on similar approaches to modify cells for therapeutic purposes.

Market impact

This patent, once granted and if successfully developed, has the potential to significantly expand the market for CAR-T cell therapies. Currently, treating T-cell malignancies with CAR-T cells is challenging due to the risk of fratricide and alloreactivity. This invention could enable new, safer, and more effective treatments for these difficult-to-treat cancers, potentially creating a new category of 'universal' or 'off-the-shelf' CAR-T products with reduced side effects, thereby increasing patient access and market size.

Claim 1 — Plain English

What this patent covers

This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (Claim 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).

The clever bit

The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.

What it does not cover

  • Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
  • Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
  • Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
  • Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
  • Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
  • Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

0/40

No citations yet

Claim breadth

20/20

Very broad protection

Recency

20/20

Granted within 5 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$108K – $346K

Midpoint $216K · 18.4 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

31 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

73

earlier patents this invention cites as foundations

View prior art →

Cite this patent

Cooper, M., & DiPersio, J. F. (2026). Gene Editing T-Cells to Fight CD7 Blood Cancers (U.S. Patent No. 12,564,648). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12564648/gene-editing-of-car-t-cells-for-the-treatment-of-t-cell-malignancies-with-chimer

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US12564648"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →gene editing patents →

Common Questions

Frequently Asked Questions

What does Gene Editing T-Cells to Fight CD7 Blood Cancers cover?

This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.

Who owns patent US 12564648?

Washington University in St. Louis owns this patent, granted in 2026.

When does this patent expire?

This patent is expected to expire on April 24, 2045, when the invention enters the public domain.

What problem does this patent solve?

Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood…

What does this patent NOT cover?

Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).

Patent monitoring

Get notified when Washington University in St. Louis files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 1, 2026 · PatentBrief is not a law firm and this is not legal advice.